Survival, Quality of Life and Breast Cancer

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2002 Jan 24

PMID 11804378

Citations 9

Authors

P Mosconi

M Colozza

M De Laurentiis

S De Placido

M Maltoni

Affiliations

Soon will be listed here.

Abstract

In recent years, evaluating quality of life (QoL) has become increasingly important as an additional measured outcome in cancer clinical trials, in particular in the field of breast cancer. This paper, after a general introduction to the present debate on the methodological issues involved in QoL evaluation, reviews results and open questions regarding the use of this measure in surgical, adjuvant and metastatic studies.

Citing Articles

High-intensity interval training in breast cancer patients: A systematic review and meta-analysis.

Chen X, Shi X, Yu Z, Ma X Cancer Med. 2023; 12(17):17692-17705.

PMID: 37587859 PMC: 10524023. DOI: 10.1002/cam4.6387.

Serum LAPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer.

Wang L, Wang Y, Zhang Q Biomed Res Int. 2022; 2022:6786351.

PMID: 36506911 PMC: 9729050. DOI: 10.1155/2022/6786351.

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.

Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E BMC Cancer. 2019; 19(1):110.

PMID: 30700265 PMC: 6354387. DOI: 10.1186/s12885-019-5287-z.

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.

Darlix A, Lamy P, Lopez-Crapez E, Braccini A, Firmin N, Romieu G BMC Cancer. 2016; 16:428.

PMID: 27387327 PMC: 4937557. DOI: 10.1186/s12885-016-2448-1.

Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer.

Kumler I, Parner V, Tuxen M, Skjoldbye B, Bergenfeldt M, Nelausen K Radiol Med. 2015; 120(6):536-41.

PMID: 25572543 DOI: 10.1007/s11547-014-0489-6.